NasdaqGS - Nasdaq Real Time Price USD

Arrowhead Pharmaceuticals, Inc. (ARWR)

15.31

-0.98

(-6.02%)

At close: May 21 at 4:00:01 PM EDT

15.20

-0.11

(-0.72%)

After hours: May 21 at 7:40:19 PM EDT

ARWR: Multiple Value Drivers for Long-Term Growth…

By David Bautz, PhD NASDAQ:ARWR READ THE FULL ARWR RESEARCH REPORT Business Update Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) has a robust pipeline of RNA interference (RNAi) therapies utilizing the company’s TRiM™ platform. The TRiM platform allows for targeting of RNAi therapeutics to seven different cell types, including liver, lung, skeletal muscle, CNS, adipose, ocular, and cardiomyocyte.

Zacks Small Cap Research 6 days ago

ARWR
-6.02%
Arrowhead Pharmaceuticals Inc (ARWR) Q2 2025 Earnings Call Highlights: Strong Financials and ...

Arrowhead Pharmaceuticals Inc (ARWR) reports robust earnings, strategic partnerships, and pipeline progress, while navigating regulatory and market uncertainties.

GuruFocus.com 8 days ago

ARWR
-6.02%
Arrowhead Research: Fiscal Q2 Earnings Snapshot

On a per-share basis, the Pasadena, California-based company said it had profit of $2.75. The results topped Wall Street expectations. The average estimate of eight analysts surveyed by Zacks Investment Research was for a loss of 6 cents per share.

Associated Press Finance 9 days ago

ARWR
-6.02%
Arrowhead Pharmaceuticals Reports Fiscal 2025 Second Quarter Results

PASADENA, Calif., May 12, 2025--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2025 second quarter ended March 31, 2025. The Company is hosting a conference call today, May 12, 2025, at 4:30 p.m. ET to discuss the results.

Business Wire 9 days ago

ARWR
-6.02%
SRPT Q1 Earnings Miss, Sales Beat, Stock Slides 21% on '25 View Cut

SRPT reports mixed first-quarter 2025 results. The stock plunges after the company significantly lowers its 2025 sales guidance.

Zacks 14 days ago

SRPT

ARWR
-6.02%

ROG.SW
Arrowhead Pharmaceuticals to Participate in May 2025 Investor Conferences

PASADENA, Calif., May 07, 2025--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming investor events:

Business Wire 14 days ago

ARWR
-6.02%
Why Arrowhead Pharmaceuticals, Inc. (ARWR) is Among the Best Small Cap Stocks to Buy with the Biggest Upside Potential

We recently published a list of Top 11 Small Cap Stocks to Buy with Biggest Upside Potential. In this article, we are going to take a look at where Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) stands against other top small cap stocks to buy with biggest upside potential. On April 24, Jill Carey Hall, BofA Securities head […]

Insider Monkey 16 days ago

ARWR
-6.02%
Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Second Quarter Results

PASADENA, Calif., April 30, 2025--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on May 12, 2025, at 4:30 p.m. ET to discuss its financial results for the fiscal 2025 second quarter ended March 31, 2025.

Business Wire 21 days ago

ARWR
-6.02%
Arrowhead Pharmaceuticals Appoints Daniel Apel as Chief Financial Officer

PASADENA, Calif., April 15, 2025--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that, effective May 13, 2025, Arrowhead’s Chief Financial Officer, Ken Myszkowski, will retire after 16 years of service to the company and will be succeeded by Daniel Apel, who has been appointed as the company’s new Chief Financial Officer. Mr. Myszkowski will continue to serve as an employee adviser to assist and facilitate an effective transition.

Business Wire last month

ARWR
-6.02%
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

PASADENA, Calif., April 04, 2025--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on April 3, 2025, the Company’s Board of Directors approved "inducement" grants to 21 new employees under Rule 5635(c)(4) of the NASDAQ Listing Rules. The grants entitle employees, in aggregate, to receive up to 34,190 restricted stock units. The grants are outside the Company’s stockholder-approved equity incentive plans and vest an

Business Wire last month

ARWR
-6.02%
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is favoured by institutional owners who hold 70% of the company

Key Insights Institutions' substantial holdings in Arrowhead Pharmaceuticals implies that they have significant...

Simply Wall St. last month

ARWR
-6.02%
Arrowhead Pharmaceuticals Stock Falls After Early-Stage Data From RNA-Based Therapeutic For Kidney Diseases

On Monday, Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) released topline results from Part 2 of a Phase 1/2 study of ARO-C3, the company’s investigational RNA interference (RNAi) therapeutic designed to reduce liver production of complement component 3 (C3) as a potential therapy for various complement-mediated diseases. ARO-C3 is designed to reduce hepatocyte production of complement C3 as a potential treatment for various complement-mediated renal diseases. The dysregulated activity of the co

Benzinga 2 months ago

ARWR
-6.02%
Arrowhead Pharmaceuticals Announces Topline Results from Part 2 of Phase 1/2 Study of ARO-C3 in Patients with IgA Nephropathy

PASADENA, Calif., March 10, 2025--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced topline results from Part 2 of a Phase 1/2 clinical study of ARO-C3, the company’s investigational RNA interference (RNAi) therapeutic designed to reduce liver production of complement component 3 (C3) as a potential therapy for various complement mediated diseases. The company plans to present additional results at a medical meeting in 2025.

Business Wire 2 months ago

ARWR
-6.02%
Arrowhead Pharmaceuticals Showcases Two Clinical-Stage RNAi-Based Candidates to Treat Obesity and Metabolic Diseases

PASADENA, Calif., March 06, 2025--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced presentation of preclinical data supporting the advancement of two first-in-class clinical stage, RNAi-based investigational therapeutics being developed for the treatment of obesity and metabolic diseases. The two candidates, ARO-INHBE and ARO-ALK7, have the potential to reduce body weight and fat mass with a novel mechanism of action that may lead to improved preservation of lean muscle mass compar

Business Wire 2 months ago

ARWR
-6.02%
Arrowhead Pharmaceuticals Launches on Rare Disease Day New Patient-Centric Resources for Those Affected by Familial Chylomicronemia Syndrome (FCS)

PASADENA, Calif., February 28, 2025--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) marks Rare Disease Day with the expansion of the We’ll Get There Soon campaign, initially launched for healthcare providers in November 2024. This new phase introduces a dedicated educational website, www.LowerMyTGs.com, and the Spotlight on FCS white paper, which provides essential resources and support for those affected by Familial Chylomicronemia Syndrome (FCS).

Business Wire 2 months ago

ARWR
-6.02%
Arrowhead Pharmaceuticals Presents Preclinical Data on ARO-ALK7 for Treatment of Obesity

PASADENA, Calif., February 25, 2025--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced preclinical results on ARO-ALK7, the company’s investigational RNA interference (RNAi) therapeutic targeting Activin receptor-like kinase 7 (ALK7) being developed as a potential treatment for obesity. The results were presented in a poster at the Keystone Symposia on Obesity and Adipose Tissue held February 23–26, 2025 in Banff, AB, Canada.

Business Wire 2 months ago

ARWR
-6.02%
Arrowhead Pharmaceuticals (ARWR): Among the Most Oversold Healthcare Stocks to Buy Now

We recently published a list of the 12 Most Oversold Healthcare Stocks to Buy Now. In this article, we are going to take a look at where Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) stands against other most oversold healthcare stocks to buy now. Are Healthcare Costs Rising in the US? Healthcare costs and spending have been rising […]

Insider Monkey 2 months ago

ARWR
-6.02%
ARWR: Multiple Catalysts Ahead in 2025…

By David Bautz, PhD NASDAQ:ARWR READ THE FULL ARWR RESEARCH REPORT Business Update Plozasiran Update On January 17, 2025, Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) announced that the U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) for plozasiran for the treatment of familial chylomycronemia syndrome (FCS), with a Prescription Drug User Fee Act (PDUFA) action

Zacks Small Cap Research 3 months ago

ARWR
-6.02%
Arrowhead Pharmaceuticals First Quarter 2025 Earnings: Misses Expectations

Arrowhead Pharmaceuticals ( NASDAQ:ARWR ) First Quarter 2025 Results Key Financial Results Net loss: US$173.1m (loss...

Simply Wall St. 3 months ago

ARWR
-6.02%
Q1 2025 Arrowhead Pharmaceuticals Inc Earnings Call

Q1 2025 Arrowhead Pharmaceuticals Inc Earnings Call

Thomson Reuters StreetEvents 3 months ago

ARWR
-6.02%

SRPT

Performance Overview

Return	ARWR	S&P 500 (^GSPC)
YTD	-18.56%	-0.63%
1-Year	-38.81%	+9.83%
3-Year	-57.72%	+49.81%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Arrowhead Pharmaceuticals, Inc. (ARWR)

ARWR: Multiple Value Drivers for Long-Term Growth…

Arrowhead Pharmaceuticals Inc (ARWR) Q2 2025 Earnings Call Highlights: Strong Financials and ...

Arrowhead Research: Fiscal Q2 Earnings Snapshot

Arrowhead Pharmaceuticals Reports Fiscal 2025 Second Quarter Results

SRPT Q1 Earnings Miss, Sales Beat, Stock Slides 21% on '25 View Cut

Arrowhead Pharmaceuticals to Participate in May 2025 Investor Conferences

Why Arrowhead Pharmaceuticals, Inc. (ARWR) is Among the Best Small Cap Stocks to Buy with the Biggest Upside Potential

Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Second Quarter Results

Arrowhead Pharmaceuticals Appoints Daniel Apel as Chief Financial Officer

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is favoured by institutional owners who hold 70% of the company

Arrowhead Pharmaceuticals Stock Falls After Early-Stage Data From RNA-Based Therapeutic For Kidney Diseases

Arrowhead Pharmaceuticals Announces Topline Results from Part 2 of Phase 1/2 Study of ARO-C3 in Patients with IgA Nephropathy

Arrowhead Pharmaceuticals Showcases Two Clinical-Stage RNAi-Based Candidates to Treat Obesity and Metabolic Diseases

Arrowhead Pharmaceuticals Launches on Rare Disease Day New Patient-Centric Resources for Those Affected by Familial Chylomicronemia Syndrome (FCS)

Arrowhead Pharmaceuticals Presents Preclinical Data on ARO-ALK7 for Treatment of Obesity

Arrowhead Pharmaceuticals (ARWR): Among the Most Oversold Healthcare Stocks to Buy Now

ARWR: Multiple Catalysts Ahead in 2025…

Arrowhead Pharmaceuticals First Quarter 2025 Earnings: Misses Expectations

Q1 2025 Arrowhead Pharmaceuticals Inc Earnings Call

Performance Overview